Zoetis Inc. $ZTS Shares Sold by Federation des caisses Desjardins du Quebec

Key Points

• The Federation des caisses Desjardins du Quebec reduced its stake in Zoetis Inc. by 13.8%, now holding approximately $50.6 million worth of shares after selling 49,394 shares in the first quarter.
• Zoetis reported a net margin of 27.83% and a revenue of $2.46 billion for the latest quarter, which exceeded analysts' expectations.
• Currently, institutional investors own 92.80% of Zoetis stock, with recent adjustments in ratings from various brokerages reflecting a cautious outlook on the stock's performance.

Federation des caisses Desjardins du Quebec reduced its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 13.8% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 307,457 shares of the company's stock after selling 49,394 shares during the quarter. Federation des caisses Desjardins du Quebec owned approximately 0.07% of Zoetis worth $50,625,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. 1248 Management LLC acquired a new position in shares of Zoetis in the 1st quarter valued at $27,000. Saudi Central Bank acquired a new stake in Zoetis in the 1st quarter valued at about $29,000. Cornerstone Planning Group LLC raised its position in Zoetis by 79.3% in the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock valued at $30,000 after purchasing an additional 88 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. raised its position in Zoetis by 87.6% in the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company's stock valued at $42,000 after purchasing an additional 120 shares in the last quarter. Finally, Sound Income Strategies LLC raised its position in Zoetis by 141.4% in the 1st quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock valued at $46,000 after purchasing an additional 164 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Analysts Set New Price Targets

ZTS has been the topic of a number of analyst reports. Piper Sandler increased their price target on Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a research report on Monday, August 11th. Leerink Partnrs lowered Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. Leerink Partners lowered Zoetis from an "outperform" rating to a "market perform" rating and reduced their price target for the company from $180.00 to $155.00 in a research report on Thursday, July 17th. Finally, Stifel Nicolaus lowered Zoetis from a "buy" rating to a "hold" rating and reduced their price target for the company from $165.00 to $160.00 in a research report on Wednesday, June 18th. Four analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, Zoetis presently has an average rating of "Moderate Buy" and an average price target of $202.43.

Zoetis Stock Down 0.0%

Shares of ZTS traded down $0.05 during mid-day trading on Friday, reaching $153.15. The company's stock had a trading volume of 1,895,936 shares, compared to its average volume of 2,304,532. The company's 50 day moving average is $153.16 and its 200 day moving average is $157.72. The stock has a market cap of $67.87 billion, a PE ratio of 26.36, a price-to-earnings-growth ratio of 2.46 and a beta of 0.89. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. Zoetis Inc. has a 12-month low of $139.70 and a 12-month high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. During the same period last year, the business posted $1.56 EPS. The company's revenue was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.